Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Aarup, K, Rotbain, EC, Enggaard, L, Pedersen, RS, Bergmann, OJ, Thomsen, RH, Frederiksen, M, Frederiksen, H, Nielsen, T, Christiansen, I, Andersen, MA & Niemann, CU 2020, 'Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib', European Journal of Haematology, bind 105, nr. 5, s. 646-654. https://doi.org/10.1111/ejh.13499

APA

Aarup, K., Rotbain, E. C., Enggaard, L., Pedersen, R. S., Bergmann, O. J., Thomsen, R. H., Frederiksen, M., Frederiksen, H., Nielsen, T., Christiansen, I., Andersen, M. A., & Niemann, C. U. (2020). Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. European Journal of Haematology, 105(5), 646-654. https://doi.org/10.1111/ejh.13499

CBE

Aarup K, Rotbain EC, Enggaard L, Pedersen RS, Bergmann OJ, Thomsen RH, Frederiksen M, Frederiksen H, Nielsen T, Christiansen I, Andersen MA, Niemann CU. 2020. Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. European Journal of Haematology. 105(5):646-654. https://doi.org/10.1111/ejh.13499

MLA

Vancouver

Aarup K, Rotbain EC, Enggaard L, Pedersen RS, Bergmann OJ, Thomsen RH o.a. Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. European Journal of Haematology. 2020 nov 1;105(5):646-654. https://doi.org/10.1111/ejh.13499

Author

Aarup, Kathrine ; Rotbain, Emelie Curovic ; Enggaard, Lisbeth ; Pedersen, Robert Schou ; Bergmann, Olav Jonas ; Thomsen, Rasmus Heje ; Frederiksen, Mikael ; Frederiksen, Henrik ; Nielsen, Tine ; Christiansen, Ilse ; Andersen, Michael Asger ; Niemann, Carsten Utoft. / Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. I: European Journal of Haematology. 2020 ; Bind 105, Nr. 5. s. 646-654.

Bibtex

@article{7160b1376f524eaeb2801af9158fda4c,
title = "Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib",
abstract = "Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front-line setting and as later-line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population-based level is still limited. Objectives: To report outcomes and AEs in a population-based cohort treated with ibrutinib outside clinical trials. Methods: We conducted a multicenter, retrospective cohort study including all patients with CLL treated with ibrutinib. Results: In total, 205 patients were included of whom 39 (19%) were treatment-na{\"i}ve. The median follow-up was 21.4 months (interquartile range (IQR), 11.9,32.8), the estimated overall survival at 12 months was 88.8% (95% confidence interval (CI); 84.3%, 93.3%), and the estimated progression-free survival at 12 months was 86.3% (95% CI; 81.3%, 91.2%). During follow-up, 200 (97.6%) patients had at least one AE and 100 (48.8%) patients had at least one grade ≥3 AE. Eighty-six patients (42.0%) discontinued ibrutinib, hereof 47 (54.7%) due to AEs and 19 (22.1%) had progression of CLL or Richter transformation. Conclusions: In our study, we find comparable, though slightly inferior, overall, and progression-free survival, and discontinuation due to toxicity was higher compared with clinical trials. Patient training and information may improve treatment adherence outside clinical trials.",
keywords = "chronic lymphocytic leukemia, epidemiology, targeted therapy",
author = "Kathrine Aarup and Rotbain, {Emelie Curovic} and Lisbeth Enggaard and Pedersen, {Robert Schou} and Bergmann, {Olav Jonas} and Thomsen, {Rasmus Heje} and Mikael Frederiksen and Henrik Frederiksen and Tine Nielsen and Ilse Christiansen and Andersen, {Michael Asger} and Niemann, {Carsten Utoft}",
note = "{\textcopyright} 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2020",
month = nov,
day = "1",
doi = "10.1111/ejh.13499",
language = "English",
volume = "105",
pages = "646--654",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Munksgaard",
number = "5",

}

RIS

TY - JOUR

T1 - Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

AU - Aarup, Kathrine

AU - Rotbain, Emelie Curovic

AU - Enggaard, Lisbeth

AU - Pedersen, Robert Schou

AU - Bergmann, Olav Jonas

AU - Thomsen, Rasmus Heje

AU - Frederiksen, Mikael

AU - Frederiksen, Henrik

AU - Nielsen, Tine

AU - Christiansen, Ilse

AU - Andersen, Michael Asger

AU - Niemann, Carsten Utoft

N1 - © 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2020/11/1

Y1 - 2020/11/1

N2 - Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front-line setting and as later-line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population-based level is still limited. Objectives: To report outcomes and AEs in a population-based cohort treated with ibrutinib outside clinical trials. Methods: We conducted a multicenter, retrospective cohort study including all patients with CLL treated with ibrutinib. Results: In total, 205 patients were included of whom 39 (19%) were treatment-naïve. The median follow-up was 21.4 months (interquartile range (IQR), 11.9,32.8), the estimated overall survival at 12 months was 88.8% (95% confidence interval (CI); 84.3%, 93.3%), and the estimated progression-free survival at 12 months was 86.3% (95% CI; 81.3%, 91.2%). During follow-up, 200 (97.6%) patients had at least one AE and 100 (48.8%) patients had at least one grade ≥3 AE. Eighty-six patients (42.0%) discontinued ibrutinib, hereof 47 (54.7%) due to AEs and 19 (22.1%) had progression of CLL or Richter transformation. Conclusions: In our study, we find comparable, though slightly inferior, overall, and progression-free survival, and discontinuation due to toxicity was higher compared with clinical trials. Patient training and information may improve treatment adherence outside clinical trials.

AB - Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front-line setting and as later-line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population-based level is still limited. Objectives: To report outcomes and AEs in a population-based cohort treated with ibrutinib outside clinical trials. Methods: We conducted a multicenter, retrospective cohort study including all patients with CLL treated with ibrutinib. Results: In total, 205 patients were included of whom 39 (19%) were treatment-naïve. The median follow-up was 21.4 months (interquartile range (IQR), 11.9,32.8), the estimated overall survival at 12 months was 88.8% (95% confidence interval (CI); 84.3%, 93.3%), and the estimated progression-free survival at 12 months was 86.3% (95% CI; 81.3%, 91.2%). During follow-up, 200 (97.6%) patients had at least one AE and 100 (48.8%) patients had at least one grade ≥3 AE. Eighty-six patients (42.0%) discontinued ibrutinib, hereof 47 (54.7%) due to AEs and 19 (22.1%) had progression of CLL or Richter transformation. Conclusions: In our study, we find comparable, though slightly inferior, overall, and progression-free survival, and discontinuation due to toxicity was higher compared with clinical trials. Patient training and information may improve treatment adherence outside clinical trials.

KW - chronic lymphocytic leukemia

KW - epidemiology

KW - targeted therapy

U2 - 10.1111/ejh.13499

DO - 10.1111/ejh.13499

M3 - Journal article

C2 - 32736410

VL - 105

SP - 646

EP - 654

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 5

ER -

ID: 60720386